

EuroTEST and HepHIV 2026 Dublin Conference, 2-3 November 2026

Venue: Radisson Blue Royal Hotel, Dublin

Overall objectives:

- Keeping testing and linkage to care on policy and implementation agendas at European and national level
- Discuss synergies between HIV, viral hepatitis, TB and STIs as well as other health priorities (i.e. cancer prevention)

Monday, 2 November 2026			
Registration opens at 12			
Time (GMT)	Room: Field Suite		Room: Green Room
11:00-13:00	From Guidance to Practice: Implementing BBV Opt-Out Testing in European Emergency Departments (open meeting)		SHIELD Joint Action Working Group (closed meeting)
	Advisory and stakeholder roundtable discussion on implementation of BBV opt-out testing in Emergency Departments		
13:15-14:45	Strengthening research capacity in Eastern Europe through the WEEPI foundation (open meeting)		
	Explore how WEEPI, a unique researcher-led research foundation, advances research excellence, scientific collaboration and evidence-based healthcare solutions in Eastern Europe. The meeting will include examples from researchers leading WEEPI-supported projects and guidance on manuscript writing.		
Time (GMT)	Room: Goldsmith 1+2		Moderators & speakers
15:00-16:00	OS	OPENING SESSION • Session objectives: Progress toward the Sustainable Development Goals and other global targets, including challenges ahead and priorities for maintaining HIV, viral hepatitis, STIs and TB on the political agenda. • Continued efforts to reduce Inequalities in access to testing for infectious diseases	Moderators: Stephen O'Hare, HepHIV2026 Conference Co-chair, HIV Ireland, Ireland Jürgen Rockstroh, HepHIV2026 Conference Co-chair, University of Bonn, Germany
15:00-15:10		Welcome to the HepHIV 2026 Dublin Conference	Conference co-chairs
15:10-15:20		Welcome message from the Minister of Health of Ireland	Minister of Health Jennifer Carroll MacNeil , Department of Health, Ireland
15:20-15:30		Keynote from the European Commission	EU Commissioner for Health and Animal Welfare Olivér Várhelyi , European Commission (video TBC)
15:30-15:40		Keynote from the European Centre for Disease Prevention and Control, ECDC	Director Pamela Rendi-Wagner , European Centre for Disease Prevention and Control, ECDC (by video)
15:40-15:50		Keynote from the WHO Regional Office for Europe	Officer-In-Charge, Director, Programme Management Corinne Capuano , WHO Regional Office for Europe (by video)
15:50-15:55		Community perspective	Executive Director Stephen O'Hare , HIV Ireland, Ireland

15:55-16:00		A clinical perspective from Ireland	Professor Patrick Mallon, Dean and Head of University College Dublin (UCD) School of Medicine; Director of Infection Research Ireland at UCD, Ireland	
16:00-16:30	Coffee break			
Time (GMT)	Room: Goldsmith 1+2		Moderators & speakers	
16:30-18:05	PL1	PLENARY SESSION 1: Zooming in on testing for infectious diseases, progress and remaining challenges in reaching the SDGs Session objectives: Status of reaching SDG targets and identifying gaps in implementation of testing programmes in Europe, discuss obstacles to linkage to care from testing services	Moderators: Stela Bivol, WHO Regional Office for Europe Jens Lundgren, CHIP, Rigshospitalet, University of Copenhagen, Denmark	
16:30-16:45	PL/01	Status on HIV, hepatitis, STIs and TB testing in Europe	Teymur Noori, European Centre for Disease Prevention and Control, ECDC	
16:45-17:00	PL/02	Implementation of testing guidelines and understanding coverage of testing at country levels	Victor Daniel Miro, Carol Davila University of Medicine and Pharmacy Bucharest, Romania	
17:00-17:15	PL/03	The role of community leadership in integrated testing services and ensuring high rates of linkage to care	Mariana Vicente, GAT, Portugal Laura Fernandez, CEEISCAT, Spain	
17:15-17:30	PL/04	Integrated testing in migrant populations – inclusion in other health services and linkage to care considerations	Lisa George-Svahn, Noaks Ark Stockholm, Region Stockholm healthcare services, Karolinska Institute, Sweden	
17:30-17:45	PL/05	Culturally sensitive and AI-based practices to improve screening and linkage to care	Pavlo Smyrnov, Alliance for Public Health (APH), Ukraine	
17:45-18:05		Discussion		
18:05-19:00	Poster session			
19:00	Reception			
	Tuesday, 3 November 2026			
Time (GMT)	Room: Goldsmith 1+2		Room: Goldsmith 3	
8:30-9:30	AS1	PARALLEL SESSION 1: Integrated testing in health care settings, including emergency departments Moderators: Johanna Brännström, South Hospital & Institute of Medicine, Karolinska Institute, Sweden & Carlos Mejia Chew, St. Vincent's University Hospital, University College Dublin, Ireland	AS2	PARALLEL SESSION 2: Integrated testing and linkage to care in community settings Moderators: Ben Collins, ReShape/International HIV Partnerships (IHP), United Kingdom & Maka Gogia, Georgian Harm Reduction Network, Georgia
8:30-8:40	AS1/01	Bloodborne virus testing in Danish emergency departments: a national baseline study D. Podlekareva, Centre of Excellence for Health, Immunity and	AS2/01	Sexy Side of the Netherlands: An Alternative Approach to Engage MSM and Transgender Newcomers in STI/HIV Testing and Care T Mouhebati, Soa Aids Nederland, the Netherlands (TBC)

		Infections (CHIP), Copenhagen University Hospital – Rigshospitalet, Denmark		
8:40-8:50	AS1/02	Data for Action: Health and economic impact of emergency department blood-borne virus opt-out testing in high-burden urban centres in Belgium, Greece, and Poland L. Bates, Aquarius Population Health, United Kingdom	AS2/02	Impact of European Testing Week on HIV, HCV and Syphilis Testing in Community-Based Services: A COBATEST Network Analysis L. Fernandez, Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, Spain (TBC)
8:50-9:00	AS1/03	Integrated HIV, Viral Hepatitis and Tuberculosis Infection Testing Across Multiple Healthcare Settings in Lithuania S. Raudonis, Vilnius University, Faculty of Medicine, Lithuania	AS2/03	HIV diagnosis and linkage-to-care outcomes within community-led integrated HIV, HCV, HBV and syphilis testing services in the Lisbon Metropolitan Area, Portugal (2021–2025) F. Gomes, GAT - Grupo de Ativistas em Tratamentos, Portugal (TBC)
9:00-9:10	AS1/04	TARGET-ID: Algorithm risk-based targeted identification and testing of people at risk of HIV, hepatitis B and hepatitis C in primary care: a feasibility study L. Werner, Queen Mary University of London, United Kingdom (TBC)	AS2/04	Psychoactive Substance Use and HIV and HCV Screening Test Outcomes Among Clients of Voluntary Counselling and Testing (VCT) Points in Poland, 2022–2025 A. Szczepański, Jagiellonian University Medical College, Poland
9:10-9:20	AS1/05	Hospital-based HCV screening as a first step towards integrated blood-borne virus testing in Italy: A national delphi consensus study L.A. Kondili, Istituto Superiore di Sanità, Italy (TBC)	AS2/05	Linkage to care for hepatitis B infection among migrant populations screened in Portugal: preliminary data from the VH-COMSAVAC project M Vicente, GAT - Grupo de Ativistas em Tratamentos, Portugal (TBC)
9:20-9:30		Discussion		Discussion
09:30-10:00	Coffee Break and posters			
Time (GMT)	Room: Goldsmith 1+2			Moderators & speakers
10:00-11:10	PL2	PLENARY SESSION 2: Optimising offer of testing for HIV, viral hepatitis, STIs and TB in medical settings – lessons learned and challenges ahead Session objectives: - Discuss the potential of testing in health care settings - Understand the obstacles of consent requirements and requirements for medical personnel across Europe	Moderators: Ann Sullivan, Chelsea and Westminster Hospital NHS Foundation Trust, United Kingdom Cary James, World Hepatitis Alliance, United Kingdom (TBC)	
10:00-10:25		PLENARY SESSION 2 – Part 1		
10:00-10:15	PL2/01	Launching the implementation guidance on BBV testing in emergency departments	Michael Rayment, Chelsea & Westminster Hospital, United Kingdom Emma Young, Barts Health NHS Trust, United Kingdom	
10:15-10:25	PL2/02	Linkage to care considerations from testing in emergency departments - a community perspective	Garry Brough, United Kingdom	
10:25-11:10		PLENARY SESSION 2 – Part 2		
10:25-11:10		Roundtable discussion Consent requirements and lay provider testing – what is the status in Europe and what can we learn	Konstantinos Protopapas, Attikon University Hospital of Athens, Greece Loreta Kondili, European Association for the Study of the Liver (EASL), Italy Raimonda Matulionyte, Vilnius University Hospital Santaros Klinikos, Vilnius University, Lithuania	

11:10-11:15	Short break			
Time (GMT)	Room: Goldsmith 1+2			Moderators & speakers
11:15-12:45	PL3	PLENARY SESSION 3: Creating an enabling environment for testing and linkage to care for HIV, viral hepatitis, STIs and TB Session objectives: - Stigma interventions after stigma surveys - Discuss how lessons learned from HIV can be used to inform the implementation of diagnostic, preventive, and therapeutic interventions for other infections.		Moderators: Teymur Noori, European Centre for Disease Prevention and Control, ECDC Denis Onyango, Africa Advocacy Foundation, United Kingdom (TBC)
11:15-11:30	PL3/01	Measuring stigma interventions in health care and other settings – where are we at?		Julia del Amo, Ministry of Health, Spain
11:30-11:45	PL3/02	Implementation projects for stigma reduction – impact and challenges?		Sarah Stutterheim, Maastricht University, The Netherlands
11:45-12:00	PL3/03	Cultural competent practices that improve screening, diagnosis, and linkage to care		Lucia Siracusa, ARNAS Civico-Di Cristina, Italy
12:00-12:15	PL3/04	Employment of peer support and reaching outside service system		Al Story, University College London Hospitals, United Kingdom
12:15-12:30	PL3/05	ECDC/WHO hepatitis stigma survey - lessons learned and next steps		Cary James, World Hepatitis Alliance, United Kingdom
12:30-12:45		Discussion		
12:45-13:40	Lunch break			
Time (GMT)	Room: Goldsmith 1+2		Room: Goldsmith 3	
13:40-14:30	AS3	PARALLEL SESSION 3: Policy implications and addressing structural barriers to implementation Moderators: Maria Prins, GGD Amsterdam, The Netherlands & Tom Platteau, Institute of Tropical Medicine, Belgium	AS4	PARALLEL SESSION 4: Focus on vulnerable populations and specific settings for interventions Moderators: Amanita Calderón-Cifuentes, Transgender Europe, TGEU, Germany & Sara Croxford, National Health Service (NHS), United Kingdom
13:40-13:50	AS3/01	Effectiveness of an online home-based self-sampling platform for HIV/STI testing in Belgium: results from the Test2Know pilot T. Platteau, Institute of Tropical Medicine, Belgium	AS4/01	More HIV Diagnoses During Event-Driven PrEP compared to Daily PrEP in the Netherlands I. J.M. Willemstein, Public Health Service Amsterdam, The Netherlands
13:50-14:00	AS3/02	From single-virus elimination to integrated testing: qualitative implementation learning from England’s Viral Hepatitis Elimination Programme A. Noonan, Viral Hepatitis Elimination Programme, Specialised Commissioning, NHS England, Unted Kingdom (TBC)	AS4/02	Experiences of stigma and discrimination among people who inject drugs in England, Wales and Northern Ireland S. Croxford, UK Health Security Agency, United Kingdom
14:00-14:10	AS3/03	Cost-effectiveness of emergency department opt-out testing for blood-borne viruses in England J. Walker, University of Bristol, United Kingdom (TBC)	AS4/03	Gaps in HBV, HCV and HPV prevention, testing and care in European prisons: findings from 17 facilities in seven countries R. Fuertes, University of Pisa, Italy
14:10-14:20	AS3/04	Using participatory knowledge translation to develop an integrated HIV, STI and hepatitis B and C strategic framework for Belgium J. Deblonde, Sciensano - Belgium Public Health Institute, Belgium (TBC)	AS4/04	Reaching the Unreached: Peer-Led Mobile HIV Testing and Outreach to Migrant and Asylum-Seeking Communities at Risk of Undiagnosed HIV and Treatment Interruption in Ireland A. Piercy, HIV Ireland, Ireland (TBC)

14:20-14:30		Discussion		Discussion
14:30-14:35	Short break			
Time (GMT)	Room: Goldsmith 1+2			Moderators & speakers
14:35-15:30	CS	CLOSING SESSION Session objectives: - Summarise the outcomes of the conference and present a draft call for action - Present and discuss opportunities to keep testing and linkage to care on policy and implementation agendas at European and national levels - Characterise sustainable testing strategies in the context of emergencies and getting closer to the targets		Moderators: Michel Kazatchkine, Senior Advisor to WHO, Switzerland Jane O'Halloran, University College Dublin, School of Medicine, Ireland
14:35-14:40	CS/01	Best Poster Award		HepHIV CO-chairs
14:40-14:50	CS/02	Focus on the Eastern European Region - innovative solutions and remaining challenges		Tetiana Deshko , Alliance for Public Health, Ukraine
14:50-15:00	CS/05	Focus on the Eastern European Region		Stela Bivol , WHO Regional Office for Europe (TBC)
15:00-15:10	CS/03	Strengthening parliamentary leadership toward the Sustainable Development Goals and other global targets related to testing and linkage to care for HIV, viral hepatitis, STIs, and TB		Lynn Ruane , UNITE Parliamentarians Network for Global Health, Ireland
15:10-15:25	CS/04	Opportunities for integrated efforts across disease areas		Kevin Fenton , Regional Director of Public Health, NHS London. Chief Advisor on HIV to Government, United Kingdom
15:25-15:30	CS/06	Conference Call to Action and closing remarks		HepHIV CO-chairs
17:00-18:00	EuroTEST Steering Committee Meeting (Closed meeting)			

Poster Category 1: Integrated testing in health care settings, including emergency departments		
PO1/01	Opt-Out HIV Testing at Croydon's Emergency Department plays a crucial role in patient safety and reduction in HIV transmission: New diagnoses 2020 to 2024	I Cormack, Croydon University Hospital, United Kingdom
PO1/03	When the algorithm reassures: AI-mediated diagnostic delay and post-test risk behaviour in a patient with HIV	M Guastavigna, SC Malattie Infettive, Amedeo di Savoia Hospital, Italy
PO1/04	Adherence to antiretroviral therapy as an HIV prevention priority in the context of late diagnosis in Latvia	T A Fernandes, Riga Stradiņš University, Institute of Public Health, Latvia

Poster Category 2: Integrated testing and linkage to care in community settings

PO2/01	Mobile Integrated Community-Based Testing for HIV, Viral Hepatitis and STIs Across Rural and Geographically Dispersed Settings: Experience from Northern Germany federal state Schleswig-Holstein	K Kandlen, Aidshilfe Schleswig-Holstein, Germany
PO2/02	Optimizing the national HIVR response: the critical role of Belgian CBOs in testing key populations	H Vermandere, Sciensano, Belgium
PO2/03	HIV and STI screening activity at Apoyo Positivo CASA community-based testing centres during 2025	J F Cabrera Solano, Apoyo Positivo, Spain
PO2/04	Bridging the Gap in Integrated HIV, Syphilis, Hepatitis B and C Testing: Overcoming Accessibility Barriers through Community-Led Strategies in Malmö, Sweden	A Ajomale, Noaks Ark Mosaik, Sweden
PO2/05	Community-based HIV and hepatitis C testing among MSM and vulnerable groups in Estonia, 2023–2025	M Kasianczuk, Estonian Network of PLWH (EHPV), Estonia
PO2/06	Bringing screening closer to those most at risk: hepatitis and HIV testing through the “Test in the City” project	P Meli, Don Giuseppe Monticelli Società Cooperativa Sociale, Italy
PO2/07	Breaking Barriers to Testing: Psychological and Epidemiological Impact of Mobile Integrated HIV, HCV and Syphilis Screening in Community Settings in Poland	N Ostrowska, Fundacja Pomorski Dom Nadziei, Poland
PO2/09	Collect2Know: an innovative low-cost device to facilitate fingerprick macro-capillary blood self-collection for HIV/STI testing	I De Baetselier, Institute Of Tropical Medicine, Belgium
PO2/10	TB/HIV Intersectional Stigma and Its Impact on Tuberculosis Infection Management in Central and Eastern Europe: A Scoping Review	Z Szulc, Master of Public Health Programme, Faculty of Medicine, Lund University, Sweden
PO2/11	Ten-Year Trends in Community-Based HIV, HBV, HCV, and Syphilis Testing and Reactivity in Portugal, 2016-2025	M J Novais, EPIUnit ITR, Instituto de Saúde Pública da Universidade do Porto, Universidade do Porto, Portugal
PO2/12	Reaching untested and young people through community outreach: rapid HIV and syphilis testing at a Pride Village event in Cagliari, Italy	E Mura, LILA Cagliari OdV, Italy

PO2/13	“Vorresti farlo più spesso?” (“Would you like to do it more often?”): combining a destigmatising multimedia campaign with mobile outreach HIV/STI testing in Cagliari, Italy — a community-based experience	E Mura, LILA Cagliari OdV, Italy
PO2/14	Promoting PrEP among people with a migration background in Belgium: experience of Plateforme’s community PrEP campaign	T G Kouadio, La Plateforme, Belgium
Poster Category 3: Policy implications and addressing structural barriers to implementation		
PO3/01	Off-track for 2030: structural inequalities in oral HIV pre-exposure prophylaxis (PrEP) access across 27 European countries, 2022–2026	F Bagyinszky, AIDS Action Europe, Germany
PO3/02	Doxy-PEP as a stress test for integrating STI prevention into HIV/PrEP systems: a qualitative implementation study from Ukraine	O Kovtun, The International Charitable Foundation "Alliance for Public Health", Ukraine
PO3/04	Beyond Diversity: How a Multi-Stakeholder Network Advances the Right to Health	I Mercurio, Don Giuseppe Monticelli Società Cooperativa Sociale, Italy
PO3/05	HCV reinfection after cure among people receiving opioid agonist therapy in Ukraine: a 13-clinic cluster trial of onsite simplified care under different provider payment models	M Filippovych, Ukrainian Institute on Public Health Policy, Ukraine
PO3/06	ITSready project: Development and early implementation of an integrated digital ecosystem for STI/HIV self-sampling, partner notification and AI-supported sexual health information for teenagers and young adults	A Colom-Cadena, Centre d’Estudis Epidemiològics de HIV/Sida i ITS de Catalunya (CEEISCAT), Departament de Salut, Generalitat de Catalunya, Spain
PO3/07	Policy Responses to Expand Access to Viral Hepatitis Testing and Care in Ukraine During Wartime	I Skrypka, State Institution "Public Health Center of the Ministry of Health of Ukraine", Ukraine
PO3/08	Public health evaluation of an antenatal hepatitis C opt-out testing pilot	M Richardson, UKHSA, United Kingdom
PO3/09	Finding the lost-to-follow-up: A Peer-Led Data Linkage and Case-Finding Model to Support Hepatitis C Elimination	A Kociejowski, UCLH Find&Treat, United Kingdom

PO3/10	From Oral PrEP to Long-Acting Formulations: The Evolution of Ukraine's National HIV Prevention Programme	I Mameletzis, World Health Organization Ukraine Country Office, Ukraine
PO3/11	Feasibility and Potential for Implementing Index HIV Self-Testing in Ukraine (pilot research)	D Kocheharova, State institution Public Health Center of the Ministry of Health of Ukraine, Ukraine
PO3/12	Designing and delivering workshops using hepatitis C surveillance data and local intelligence to drive public health action and support regional progress to elimination goals in England	V Morris, UK Health Security Agency, United Kingdom
PO3/13	From Research to Advocacy: Developing a Multilingual Media Content to Support TB Infection Screening in People with HIV in Central and Eastern Europe	G Pawłowska, Bachelor of Management and Sociology, Department of Management, Kozminski University, Warsaw
PO3/14	Seeing Beyond the Diagnosis: Using Visual Storytelling to Challenge HIV and Viral Hepatitis Stigma Through the PLHIV Documentary	S Doyle, PLHIV Documentary, Ireland
Poster Category 4: Focus on vulnerable populations and specific settings for interventions		
PO4/01	Mobile Outreach for Viral Hepatitis Micro-Elimination in Croatian Prisons: Improving Access to Diagnostics and Linkage to Care (2023–2025)	T Reic, Croatian Society for the Liver Diseases "Hepatos", Croatia
PO4/02	Implementing Community-Led Integrated HIV, HCV and Syphilis Testing in Polish Prisons: Experience from Foundation for Social Education	M Ankiersztejn-Bartczak, Foundation for Social Education, Poland
PO4/03	Nine Years of Integrated Community-Based Testing within a Harm Reduction Programme for People Who Inject Drugs by Foundation for Social Education in Warsaw, Poland	M Ankiersztejn-Bartczak, Foundation for Social Education, Poland
PO4/04	Efficacy of an Online HIV/STI Screening Addressed to Men Who Have Sex with Men Users of PrEP in Spain (TESTATE PrEP)	C Agustí, CEEISCAT-Agència de Salut Pública de Catalunya, Spain

PO4/05	HIV Self-Testing in Ukraine: Scaling Differentiated Testing Models Among Key Populations (2025)	S Vynohradova, Public Health Center of the MOH of Ukrain, Ukraine
PO4/06	Integrated biobehavioural survey among people who inject drugs (PWID) in Ukraine, 2023	M Moshura, Public Health Center of the MOH of Ukrain, Ukraine
PO4/07	Optimizing HIV, HBV and HCV screening via online self-sampling among GBMSM and trans people in Spain: The Pan-TESTATE project	H S Perea Cortés, Centre d'Estudis Epidemiològics de HIV/Sida i ITS de Catalunya (CEEISCAT), Spain
PO4/08	Women and HIV PrEP in Ukraine: Expanding Access Beyond Traditional Key Populations	O Klymova, State Institution "Public Health Center of the Ministry of Health of Ukraine", Ukraine
PO4/09	Integrating HIV, Hepatitis, and STI Services into Mental Health Care amidst Wartime Challenges: Lessons from Ukraine	V Virchenko, Taras Shevchenko National University of Kyiv, Ukraine
PO4/10	Four Years of STI Screening in a Portuguese University: Prevalence, Trends and Public Health Implications	A M Matos, LACUC - Clinical Laboratory Analysis from University of Coimbra, Portugal
PO4/11	Hepatitis B knowledge and self-reported testing and vaccination history among populations with increased risk in Georgia	L Gulbiani, Health Research Union, Georgia
PO4/12	The paradox of high coverage: persistent HCV reinfection in care-engaged MSM networks	D Calzavara, Prisma, Belgium
PO4/13	Arrested because we help": psychological burden, demotivation and impact of arrests on MSM community counsellors in Dakar, Senegal – a mixed-methods study after the February 2026 media crisis	E K Diouf, DLSI – Ministry of Health of Senegal, Senegal
PO4/14	Considerations for implementing pharmacist testing programs for HIV and Hepatitis C – Analysis from two Canadian studies in community pharmacy and rural corrections sites	D Kelly, Memorial University of Newfoundland & Labrador, Canada

PO4/15	Crosslink: Building on Lessons Learned to Improve Access to HIV/STI Services for Mobile and Migrant Population	T Mouhebati Soa Aids Nederland, the Netherlands
PO4/16	HIV self-testing among people who inject drugs during the war in Ukraine: sustained coverage through NGO-led community-based prevention programs, 2023–2025	L Legkostup, Public Health Center of the MOH of Ukraine, Ukraine
PO4/17	A European prison sentinel network for viral hepatitis, HPV and harm reduction: structure and baseline feasibility in the PACE project	V Casigliani, University of Pisa, Italy
PO4/18	Formative Research of a Mobile Drug Consumption Room in Brno: Addressing Public Injecting and HCV Risks in a Socially Excluded Location	B Janikova, First Faculty of Medicine, Charles University, Czech Republic
PO4/19	Starting Opioid Agonist Therapy (OAT) But Missing the Test: Opportunities to Improve Hepatitis C Screening in Newfoundland and Labrador, Canada	C Balsom, Memorial University, Canada
PO4/20	Breaking Barriers in the Czech Republic: A Unique NGO-Led Model of Integrated Harm Reduction and DAA Treatment for PWUDs	B Janikova, Společnost Podane Ruce, Czech Republic
PO4/21	Mental Health and Prevention Interventions targeting LGBTQ+ Asylum Seekers	J Farrell, Choices Support Center, the Netherlands